TCA
MLYS icon

Troluce Capital Advisors’s Mineralys Therapeutics MLYS Stock Holding History

Troluce Capital Advisors’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.7M Buy
+655,000
New +$19.2M 1.09% 34

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Troluce Capital Advisors's MLYS Position: Q1 2026 in Review

Troluce Capital Advisors opened a new position in Mineralys Therapeutics (MLYS) in Q1 2026: 655,000 shares worth $17.7M. The stake represents 1.09% of the portfolio and ranks #34 among its holdings.

214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Troluce Capital Advisors held 655,000 shares of Mineralys Therapeutics worth $17.7M as of Q1 2026.
  • Mineralys Therapeutics was a new Troluce Capital Advisors position in Q1 2026.
  • Mineralys Therapeutics made up 1.09% of Troluce Capital Advisors's portfolio in Q1 2026, its #34 holding.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Troluce Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.